Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ADCT Relative to the S&P 500

ADCT Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the ADC Therapeutics SA (NYSE:ADCT) seasonal charts above shows that a Buy Date of October 25 and a Sell Date of January 13 has resulted in a geometric average return of 20.77% above the benchmark rate of the S&P 500 Total Return Index over the past 4 years. This seasonal timeframe has shown positive results compared to the benchmark in 3 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 4 years by an average of 76.76% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 4 years of data is available for shares of ADCT, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

To download ADCT seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ADCT